Loading
institutionsInstitution
University College London Hospitals / UCL Cancer Institute
Central London's university hospital and one of two NHS proton beam therapy centres, backed by UCL's cancer institute and its CAR-T and lung cancer evolution research.
Also called: UCLHUCL Cancer InstituteUCLH Proton Beam Therapy Centre
Overview
UCLH runs one of the UK's largest cancer services, including the University College Hospital Macmillan Cancer Centre, a national proton beam therapy centre that opened in 2021, and a teenage and young adult cancer unit. The UCL Cancer Institute hosts the TRACERx lung cancer evolution study with the Francis Crick Institute under Charles Swanton, Martin Pule's CAR-T engineering group that spun out Autolus, and Sergio Quezada's work on clonal neoantigen T-cell therapy behind Achilles Therapeutics. The MRC Clinical Trials Unit at UCL coordinated the STAMPEDE prostate cancer platform trial and the Cancer Research UK & UCL Cancer Trials Centre runs many national trials. UCLH is also a major site for lung screening studies and adult ALL cell therapy.
Location
London, GB
Type
hospital · University College London
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#17 · 102 points (0 Newsweek + 0 NCI + 102 from 51 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to University College London, including child institutions. 2,376 works · 28,940 citations · 78% open access · 10% clinical trials · 3% reviews.
Oncology works per year
5302022
4952023
4932024
4972025
3612026
Most works
- Claire Roddie86 works
- Maeve O’Reilly62 works
- Georgios Lyratzopoulos51 works
- Martin Pulé46 works
- Jonathan A. Ledermann34 works
- Charles Swanton33 works
- Sara Ghorashian31 works
- Abigail Fisher30 works
- Giuseppe Fusai30 works
- Omer F. Ahmad29 works
Most cited
- Proton beam therapy
- TRACERx and cancer evolution
- CAR-T engineering
- MRC Clinical Trials Unit (STAMPEDE)
- Teenage and young adult cancer
Caroline Moore
Professor of Urology and Head of Urology, Department of Targeted Intervention, University College London; Honorary Consultant Urologist, University College London Hospitals
MRI-guided diagnosis of prostate cancerActive surveillanceFocal therapy
The UCL urologist who has spent her career on the two questions that decide whether a man with prostate cancer is harmed by being diagnosed: who needs a biopsy, and who needs treating at all.
David Probert
Chief Executive
Hospital managementNHS leadership
Chief Executive of University College London Hospitals NHS Foundation Trust, which runs the UCH Macmillan Cancer Centre.
Gerhardt Attard
Medical oncologist, UCL Cancer Institute and University College London Hospitals
Prostate cancerAndrogen receptor signallingCirculating tumour DNA
London oncologist who helped develop abiraterone and led the STAMPEDE analysis showing that two years of abiraterone alongside hormone therapy and radiotherapy improves survival in high-risk localised prostate cancer.
John Bridgewater
Professor of Medical Oncology, UCL Cancer Institute; Consultant Medical Oncologist, University College London Hospitals; Medical Adviser, AMMF
Biliary tract cancerCarcinoma of unknown primaryGastrointestinal oncology
Senior author of the UK's two standard-setting biliary trials, ABC-02 and BILCAP, chief investigator of ABC-06, and UK lead of the first-line precision medicine trial SAFIR-ABC10.
Jonathan A. Ledermann
Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH
Ovarian cancerPARP inhibitorsCooperative-group trials
Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.
Mahesh K. B. Parmar
Director, MRC Clinical Trials Unit at UCL; Professor of Medical Statistics and Epidemiology
Multi-arm multi-stage trial designProstate cancer trialsBiostatistics
Statistician who invented the multi-arm multi-stage design behind STAMPEDE, letting one trial test many treatments at once.
Mark Emberton
Professor of Interventional Oncology and Dean of the Faculty of Medical Sciences, University College London
Prostate cancer diagnosticsMRI-guided biopsyFocal therapy
Urologist behind PROMIS and PRECISION, which put MRI before biopsy in the prostate cancer pathway.
Mary McCormack
Consultant Clinical Oncologist, University College London Hospitals
Cervical cancerChemoradiotherapyInduction chemotherapy
Led INTERLACE, which showed a short course of chemotherapy before chemoradiation cuts cervical cancer deaths using cheap, available drugs.
Usha Menon
Professor of Gynaecological Cancer, MRC Clinical Trials Unit at UCL
Ovarian cancer screeningPopulation trialsRisk algorithms
Led UKCTOCS, the 200,000-woman trial that found ovarian cancer screening does not save lives despite detecting cancers earlier.
Charles Swanton
Deputy Clinical Director, Francis Crick Institute; Chief Clinician, Cancer Research UK
Tumour evolutionLung cancerCirculating tumour DNA
Leads TRACERx, the study that follows lung cancers as they evolve, and showed how air pollution can trigger lung cancer without new mutations.
Nicholas James
Professor of Prostate and Bladder Cancer Research, ICR; Consultant Clinical Oncologist, Royal Marsden
Prostate cancerBladder cancerMulti-arm platform trials
Nicholas James is chief investigator of STAMPEDE, the platform trial that reshaped treatment of advanced prostate cancer.
Similar pages
- InstitutionImperial College Healthcare NHS Trust / Imperial College London Cancer Research
Shares PROMIS, TRANSFORM, AMMF, the Cholangiocarcinoma Charity, Precision-Panc.
- PersonHashim U. Ahmed
Shares Caroline Moore, PROMIS, TRANSFORM, Focused ultrasound & histotripsy.
- InstitutionLeeds Cancer Centre, St James's University Hospital
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, SAFIR-ABC10, UK specialist HPB cancer centres.
- InstitutionNewcastle Cancer Centre / Northern Centre for Cancer Care
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres.
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres.
- Key paperTRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse
Shares Charles Swanton, The Francis Crick Institute, Neoantigen, Cancer Research UK.
- InstitutionUniversity Hospitals Birmingham / University of Birmingham Cancer Research Centre
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Cancer Research UK.
- InstitutionThe Christie NHS Foundation Trust
Shares ABC-12, AMMF, the Cholangiocarcinoma Charity, Precision-Panc, Proton therapy machines: cyclotrons, synchrotrons and single-room systems.
cancers
fronts
technologies
companies
institutions
terms
trials
ABC-07ABC-12EUROPACFOCUS4FoRTHemithoracic irradiation with proton therapy in malignant pleural mesothelioma (UCL)HERIZON-BTC-01Lung-SEARCHPATCH (Prostate Adenocarcinoma Transcutaneous Hormone)Precision-PancPROMISQUARTZRADICALS-HDRADICALS-RTSAFIR-ABC10SEVILLASTAMPEDESUMMIT (lung health check study)TARGIT-A (targeted intraoperative radiotherapy)TRACERxTRANSFORM